Clinical trials: Oesophageal Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
- Trial name
- PROSPECT-ESO (NCT05780736)
- Where
- 24 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Radiation Therapy, Cancer
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Collect blood samples and associated clinical data prior to, during, and post radiation treatment.
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder
- Trial name
- RADIANT (NCT03133286)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- DxTerity Diagnostics
Barrett's Esophagus, High Grade Dysplasia
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
The purpose of this study is to evaluate the safety and effectiveness of the CryoSpray Ablation System to treat esophageal low grade dysplasia (LGD) or high grade dysplasia (HGD) within Barrett's Esophagus (BE).
- Conditions
- Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia
- Trial name
- ICE (NCT00526786)
- Testing
- CryoSpray Ablation System (510(k) NO: K070893)
- Where
- 16 sites in United States
- Volunteers
- 78 people
- Sponsor
- CSA Medical, Inc.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Esophageal Fistula, Esophageal Neoplasms
Removal of the Evolution® Esophageal Stent - Fully Covered
The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
- Conditions
- Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Esophageal Stenosis
- Trial name
- CLARITY (NCT01900691)
- Testing
- Evolution® Esophageal Stent - Fully Covered
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cook Group Incorporated
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Esophageal Cancer
A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer
This is a phase 1 study to evaluate safety and tolerability of Telomelysin (OBP-301) in combination with radiation therapy in patient with esophageal cancer who are not applicable to standard therapy.
- Trial name
- NCT03213054
- Testing
- OBP-301, Radiation
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Oncolys BioPharma Inc
Barrett's Esophagus
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
The primary objective of this study is to determine the percentage segment regression after spray cryotherapy in a dose-escalation study performed in patients with dysplastic Barrett's Esophagus (BE) using trūFreeze™ spray…
- Trial name
- DOSE (NCT01845454)
- Testing
- trūFreeze™ Spray Cryotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- CSA Medical, Inc.
Triple Negative Breast Cancer, Head & Neck Cancer
PCA062 in pCAD-positive Tumors.
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
- Conditions
- Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
- Trial name
- NCT02375958
- Testing
- PCA062
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Papilloma Viral Infection, Papillomavirus Infections
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
A randomized, double-blind, phase II clinical trial was conducted versus placebo in 110 patients with esophageal human papillomavirus.
- Conditions
- Papilloma Viral Infection, Papillomavirus Infections, Esophageal Viral Wart, Esophageal Verrucous Carcinoma
- Trial name
- NCT03584308
- Testing
- Viusid®, Glizigen®
- Where
- Cuba
- Volunteers
- 110 people
- Sponsor
- Catalysis SL
Esophageal Cancer
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic…
- Trial name
- NCT00003326
- Testing
- paclitaxel
- Where
- 30 sites in United States
- Volunteers
- 100 people
- Sponsor
- Theradex
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
- Trial name
- NCT07578571
- Testing
- IM-1617
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.